It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Little is known about the features and outcomes of Brazilian patients with pancreatic cancer. We sought to describe the socio-economic characteristics, patterns of health care access, and survival of patients diagnosed with malignant pancreatic tumors from 2000 to 2014 in São Paulo, Brazil. We included patients with malignant exocrine and non-classified pancreatic tumors according to the International Classifications of Disease (ICD)-O-2 and -O-3, diagnosed from 2000 to 2014, who were registered in the FOSP database. Prognostic factors for overall survival (OS) in the subgroup of patients with ductal or non-specified (adeno)carcinoma were evaluated using Cox proportional hazard model. The study population consists of 6855 patients. Median time from the first visit to diagnosis and treatment were 13 (Interquartile range [IQR] 4–30) and 24 (IQR 8–55) days, respectively. Both intervals were longer for patients treated in the public setting. Median OS was 4.9 months (95% confidence interval [95% CI] 4.7–5.2). Increasing age, male gender, lower educational level, treatment in the public setting, absence of treatment, advanced stage, and treatment from 2000 to 2004 were associated with inferior OS. From 2000–2004 to 2010–2014, no improvement in OS was seen for patients treated in the public setting. Survival of patients with malignant pancreatic tumors remains dismal. Socioeconomical variables, especially health care funding, are major determinants of survival. Further work is necessary to decrease inequalities in access to medical care for patients with pancreatic cancer in Brazil.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 A.C. Camargo Cancer Center, Medical Oncology Department, São Paulo, Brazil (GRID:grid.413320.7) (ISNI:0000 0004 0437 1183)
2 A.C. Camargo Cancer Center, Abdominal Surgery Department, São Paulo, Brazil (GRID:grid.413320.7) (ISNI:0000 0004 0437 1183); Baylor College of Medicine, Department of Medicine/Epidemiology and Population Sciences, Houston, USA (GRID:grid.39382.33) (ISNI:0000 0001 2160 926X)
3 A.C. Camargo Cancer Center, Pathology Department, São Paulo, Brazil (GRID:grid.413320.7) (ISNI:0000 0004 0437 1183)
4 A.C. Camargo Cancer Center, Abdominal Surgery Department, São Paulo, Brazil (GRID:grid.413320.7) (ISNI:0000 0004 0437 1183)
5 A.C. Camargo Cancer Center, Department of Epidemiology and Statistics-International Research Center (CIPE), São Paulo, Brazil (GRID:grid.413320.7) (ISNI:0000 0004 0437 1183)